

# HPV vaccines indicator

---

## Safety of the intervention

### Type, including severity, consequences and frequency of short- and long-term adverse events following vaccination

As of the end of 2024, more than 700 million doses of HPV vaccine have been distributed since licensure in 2006. <sup>1, 2</sup> Post-licensure surveillance has detected no serious safety issues to date except rare reports of anaphylaxis. The risk of anaphylaxis has been characterized as approximately 1.7 cases per million doses. <sup>3</sup> A systematic review of studies on the safety of HPV vaccines found little-to-no difference among recipients of bivalent, quadrivalent and nonavalent HPV vaccines with regard to serious adverse events. <sup>4, 5</sup>

---

## Sources

1.

World Health Organization (no date). Global Advisory Committee on Vaccine Safety: human papillomavirus vaccines. Geneva: World Health Organization (<https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines>, accessed 23 June 2025).

2.

World Health Organization (2024). Global vaccine market report 2024. Geneva: World Health Organization (<https://www.who.int/publications/m/item/global-vaccine-market-report-2024>, accessed 23 June 2025).

3.

World Health Organization (2017). HPV vaccine: rates of adverse events following immunization. Geneva: World Health Organization (<https://www.who.int/publications/m/item/hpv-vaccine-rates-information-sheet> , accessed June 24, 2025)

4.

Human papillomavirus vaccines: Safety topic page [website]. Geneva: World Health Organization; 2022 (<https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety>, accessed 19 June 2025).

5.

Demicheli V, Jefferson T, Ferroni E, Rivetti A (2022). Vaccines for preventing human papillomavirus infection in females. Cochrane Database Syst Rev. 2022(5):CD015363. <https://doi.org/10.1002/14651858.CD015363.pub2>.